Determination of cellular uptake and intracellular levels of Cenersen (Aezea®, EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells-Reference-Cited by-同舟云学术

Determination of cellular uptake and intracellular levels of Cenersen (Aezea®, EL625), a p53 antisense oligonucleotide in acute myeloid leukemia cells

Published:2012-12 Issue: Volume:71 Page:228-232
ISSN:0731-7085
Container-title:Journal of Pharmaceutical and Biomedical Analysis
language:en
Short-container-title:Journal of Pharmaceutical and Biomedical Analysis

Author:

Alachkar Houda,Xie Zhiliang,Marcucci Guido,Chan Kenneth K.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Spectroscopy,Drug Discovery,Pharmaceutical Science,Analytical Chemistry

Reference23 articles.

1. Acute myeloid leukaemia

2. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461

3. Chemosensitisation of malignant melanoma by BCL2 antisense therapy

4. Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?

5. p53: puzzle and paradigm.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials;Signal Transduction and Targeted Therapy;2023-09-06

2. Ribosomopathies: New Therapeutic Perspectives;Cells;2020-09-11

3. A critical analysis of methods used to investigate the cellular uptake and subcellular localization of RNA therapeutics;Nucleic Acids Research;2020-07-09

4. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches;Advances in Biological Regulation;2018-01

5. Delivery is key: lessons learnt from developing splice‐switching antisense therapies;EMBO Molecular Medicine;2017-03-13